Crsp zacks score
http://nt8.zacks.com/zackscharts/page.aspx?code=crsp WebApr 9, 2024 · 3/16/2024 - Zacks Investment Research. 21,440 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by Continental Investors Services Inc. 3/16/2024 - Zolmax. CRISPR Therapeutics AG (CRSP) Stock Moves -0.51%: What You Should Know. 3/15/2024 - Zacks Investment Research.
Crsp zacks score
Did you know?
WebApr 11, 2024 · Analyst Forecast. According to 35 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $85.88, which is an increase of 89.16% from the latest price. WebCRSP Complete CRISPR Therapeutics AG stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... Apr. 4, 2024 at 12:43 p.m. ET on Zacks.com. CRISPR ...
WebJan 8, 2024 · Shares of CRISPR Therapeutics ( CRSP 3.56%) sank 50.5% in 2024, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2024's trading, investors reassessed the ... WebSep 17, 2024 · The stock is currently a #3 (Hold) on the Zacks Rank. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks …
WebJun 4, 2024 · As of the end of day on the 2024-04-11, the price of an CRISPR Therapeutics (CRSP) share was $45.41. What is the 52-week high and low for CRISPR Therapeutics … WebFree Cash Flow (TTM) is a widely used stock evaluation measure. Find the latest Free Cash Flow (TTM) for CRISPR Therapeutics (CRSP)
WebApr 11, 2024 · The CRISPR Therapeutics stock price gained 1.34% on the last trading day (Thursday, 6th Apr 2024), rising from $44.80 to $45.40. During the last trading day the stock fluctuated 3.83% from a day low at $44.03 to a day high of $45.71. The price has risen in 7 of the last 10 days and is up by 5.24% over the past 2 weeks.
WebApr 6, 2024 · According to the issued ratings of 18 analysts in the last year, the consensus rating for CRISPR Therapeutics stock is Hold based on the current 1 sell rating, 8 hold ratings and 9 buy ratings for CRSP. The average twelve-month price prediction for CRISPR Therapeutics is $72.89 with a high price target of $123.00 and a low price target of $39.00. ontogeny and phylogeny definitionWebJul 24, 2024 · Increase Your Credit Score About Us Our Purpose: To make the world smarter, happier, and richer. ... (CRSP 0.71%). This company has performed splendidly since its IPO in late 2016, returning 792.5 ... ios swift alamofireWeb21 hours ago · Price To Cash Flow is a widely used stock evaluation measure. Find the latest Price To Cash Flow for CRISPR Therapeutics (CRSP) ios swift 3 check microphone permissionWebApr 12, 2024 · Since there are currently no approved drug therapies for the treatment of FAP, Flynpovi has become a potentially life-changing therapeutic option for patients … ontogeny and phylogeny wikipediaWebCRISPR Therapeutics AG (CRSP) $121.63 (As of 04/06/21) Price Target (6-12 Months): $128.00 ... Prior Recommendation: Underperform Short Term:€1-3 Months Zacks Rank:€(1-5) Zacks Style Scores: 3-Hold VGM:F € Value: F Growth: F Momentum: F Summary CRISPR Therapeutics’ lead candidate, CTX001, a CRISPR gene-editedtherapy ... ontogeny does not recapitulate phylogenyWebCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to … ontogeny c storage timeWebJun 25, 2024 · The CRSP US Total Market Index currently includes more than 3,700 stocks with a median market capitalization of $1.4 billion. For the 12 months through March 2024, the index gained 62.5%. The ... ios survey app